IT1404011B1 - Nanovettore coniugato con tsh per il trattamento del cancro della tiroide - Google Patents

Nanovettore coniugato con tsh per il trattamento del cancro della tiroide

Info

Publication number
IT1404011B1
IT1404011B1 ITRM2010A000629A ITRM20100629A IT1404011B1 IT 1404011 B1 IT1404011 B1 IT 1404011B1 IT RM2010A000629 A ITRM2010A000629 A IT RM2010A000629A IT RM20100629 A ITRM20100629 A IT RM20100629A IT 1404011 B1 IT1404011 B1 IT 1404011B1
Authority
IT
Italy
Prior art keywords
nanovector
tsh
conjugated
treatment
thyroid cancer
Prior art date
Application number
ITRM2010A000629A
Other languages
English (en)
Inventor
Donato Cosco
Massimo Fresta
Donatella Paolino
Diego Russo
Original Assignee
Uni Degli Studi Magna Graecia Di Catanzaro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uni Degli Studi Magna Graecia Di Catanzaro filed Critical Uni Degli Studi Magna Graecia Di Catanzaro
Priority to ITRM2010A000629A priority Critical patent/IT1404011B1/it
Priority to PCT/IB2011/052816 priority patent/WO2012073125A1/en
Publication of ITRM20100629A1 publication Critical patent/ITRM20100629A1/it
Application granted granted Critical
Publication of IT1404011B1 publication Critical patent/IT1404011B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
ITRM2010A000629A 2010-12-03 2010-12-03 Nanovettore coniugato con tsh per il trattamento del cancro della tiroide IT1404011B1 (it)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ITRM2010A000629A IT1404011B1 (it) 2010-12-03 2010-12-03 Nanovettore coniugato con tsh per il trattamento del cancro della tiroide
PCT/IB2011/052816 WO2012073125A1 (en) 2010-12-03 2011-06-27 Tsh-conjugated nanocarrier for the treatment of thyroid cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM2010A000629A IT1404011B1 (it) 2010-12-03 2010-12-03 Nanovettore coniugato con tsh per il trattamento del cancro della tiroide

Publications (2)

Publication Number Publication Date
ITRM20100629A1 ITRM20100629A1 (it) 2012-06-04
IT1404011B1 true IT1404011B1 (it) 2013-11-08

Family

ID=43737260

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM2010A000629A IT1404011B1 (it) 2010-12-03 2010-12-03 Nanovettore coniugato con tsh per il trattamento del cancro della tiroide

Country Status (2)

Country Link
IT (1) IT1404011B1 (it)
WO (1) WO2012073125A1 (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102071731B1 (ko) * 2011-12-19 2020-01-30 젠자임 코포레이션 갑상선 자극 호르몬 조성물
CN103110931B (zh) * 2013-03-19 2015-08-19 广州迈达康医药科技有限公司 制备罗咪酯肽脂质体的方法
WO2015117136A1 (en) 2014-02-03 2015-08-06 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
CN112656764B (zh) * 2020-12-28 2022-09-02 吉林大学 一种紫杉醇铂类共载靶向长循环脂质体及应用
WO2023203249A1 (en) 2022-04-22 2023-10-26 Universität Heidelberg Composition comprising cytidine analogs and uses and methods thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH672733A5 (it) 1987-05-22 1989-12-29 Bracco Ind Chimica Spa
DE4402867C1 (de) * 1994-01-31 1995-06-14 Rentschler Arzneimittel Liposomen enthaltend darin verkapselte Proteine, Verfahren zu ihrer Herstellung sowie diese Liposomen enthaltende pharmazeutische und kosmetische Zubereitungen
DE4432378A1 (de) 1994-09-12 1996-03-14 Bayer Ag Injizierbare liposomale Arzneizubereitungen
US20070077258A1 (en) 2005-03-29 2007-04-05 Guilford F T ADMINISTRATION OF GLUTATHIONE (REDUCED) VIA INTRAVENOUS OR ENCAPSULATED IN LIPOSOME FOR THE AMELIORATION OF TNF-alpha EFFECTS AND FLU-LIKE VIRAL SYMPTOMS AND TREATMENT AND PREVENTION OF VIRUS
KR20080082956A (ko) 2005-09-15 2008-09-12 노보솜 아게 양쪽성 리포솜의 개선 또는 양쪽성 리포솜에 관련된 개선
EP1992688B1 (en) 2006-02-15 2016-06-22 Mie University Method of constructing recombinant proteoliposome for diagnostic use
CA2743139C (en) * 2008-11-10 2019-04-02 Alnylam Pharmaceuticals, Inc. Novel lipids and compositions for the delivery of therapeutics

Also Published As

Publication number Publication date
ITRM20100629A1 (it) 2012-06-04
WO2012073125A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
DK2707030T3 (da) Cancerbehandlinger
BR112014007603A2 (pt) métodos de tratamento do câncer
HK1202253A1 (en) Combination treatment of cancer
HK1201413A1 (en) Treatment of breast cancer
BR112013024211A2 (pt) tratamento de tumores sólidos
BR112014012880A2 (pt) tratamento imunogênico do câncer
SMT201600235B (it) Predittori per il trattamento del cancro
BR112013011659A2 (pt) métodos de tratamento do câncer
SMT201600253B (it) Terapia di combinazione per il trattamento del cancro della mammella
DK3055331T3 (da) Konjugerede antistoffer mod ly75 til cancerbehandling
EP2903644A4 (en) TREATMENT OF CANCER
EP2768499A4 (en) INDOMETACIN ANALOGUES FOR THE TREATMENT OF CANCER PROSTATE RESISTANT TO CASTRATION
IL228430A0 (en) Cancer treatment
EP2600896A4 (en) TREATMENT OF BREAST CANCER WITH ANTI-IL-19 ANTIBODIES
IT1404011B1 (it) Nanovettore coniugato con tsh per il trattamento del cancro della tiroide
EP2817011A4 (en) TREATMENT OF CANCER
EP2575459A4 (en) CANCER TREATMENT WITH WORDMAN ANALOGA
GB201217890D0 (en) Treatment of cancer
GB201121783D0 (en) Treatment of cancer
GB201121791D0 (en) Combination treatment of cancer
GB201017354D0 (en) Treatment of cancer
GB201208296D0 (en) Treatment of cancer